

PATENT ATTORNEY DOCKET NO. 50026/012003

Certificate of Mailing: Date of Deposit: February 19, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine M. Colbert

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OF RECEIVED

Applicant:

Keiya Ozawa et al.

Art Unit:

1636 FEB **2** 7 2004

Serial No.:

09/905,592

Examiner:

R. Akhavan

Filed:

July 13, 2001

Customer No.:

21559

Title:

GENE THAT IMPARTS SELECTIVE PROLIFERATIVE ACTIVITY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office Action on the merits, but before 02/26/2004 SZEWDIE1 00000062 09905592
01 FC:1806 180.00 0P

receipt of a final Office Action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee of 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 19 Fishutty 2004

James D. DeCamp, Ph.D. Reg. No. 43,580

Rag. Mo. 52, 290

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045



RECEIVED

FEB 2 7 2004

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COM (MODIFIED) PATENT AND TRADEMARK				Serial No.		50026/012003		
						09/905,592		
INFORMATION DISCLOSURE				Applicant		Keiya Ozawa et al.		
STATEMENT BY APPLICANT (Use several sheets if necessary)				Filing Date		July 13, 2001		
(coo const. should it hecostally)				Group		1636		
(37 C.F.R. § 1.98(b))				IDS Filed		February	February 19, 2004	
U.S. PATENTS								
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION								
Examiner's Initials	Document Number	Publication Date	Country Patent Of		Class	Subclass	Translation (Yes/No)	
·	·							
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)								
	Anderson, "Human Gene Therapy" Nature 392(Supp.):25-30 (1998).							
	Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" Nature 421:678 (2003).							
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).							
	Juengst, "What Next for Human Gene Therapy" BMJ 326:1410-1411 (2003).							
	Kakuta et al., "Inhibition of B16 Melanoma Experimental Metastasis by Interferon-γ through Direct Inhibition of Cell Proliferation and Activation of Antitumour Host Mechanisms," <i>Immunology</i> 105:92-100 (2002).							
	Kmiec "Gene Therapy" American Scientist 87:240-247 (1999).							
	Marcinkowska and Więdłocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," Acta Biochimica Polonica 49(3):735-745 (2002).							
	Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," The Journal of Biological Chemistry, 269(8):5976-5980 (1994).							
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).							
	Verma and Somia, "Gene Therapy-Promises, Problems and Prospects," Nature 389:239-242 (1997).							
	Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent in Vivo," The Journal of Biological Chemistry, 270(40):23322-23329 (1995).							
	Wimmel et al., "Autocrine Growth Inhibition by Transforming Growth Factor β-1 (TGFβ-1) in Human Neuroendocrine Tumour Cells," <i>Gut</i> 52:1308-1316 (2003).							
EXAMINER			DATE CO	DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.								